-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 21, 2025

Understanding CGM Metrics

Author(s)Davida Kruger, MSN, APN-BC, BC-ADM , Jaime Murillo, MD, FACC, FASE , Ian Neeland, MD, FAHA, FACC

Experts discuss the relative value of different continuous glucose monitoring (CGM) metrics (glucose management indicator [GMI], time in range, glucose variability) in assessing glycemic control and how these outcomes vary across different patient populations.

Episodes in this series

1 KOL is featured in this series.

EP. 1 CGM: Redefining Type 2 Diabetes Management

EP. 2 Key Benefits of CGM Technology

EP. 2 Key Benefits of CGM Technology

EP. 3 CGM's Impact on Clinical Inertia

EP. 3 CGM's Impact on Clinical Inertia

EP. 4 CGM vs Traditional Monitoring

EP. 4 CGM vs Traditional Monitoring

EP. 5 Understanding CGM Metrics

EP. 5 Understanding CGM Metrics

EP. 6 Health Care System Integration

EP. 6 Health Care System Integration

EP. 7 CGM Coverage and Access

EP. 7 CGM Coverage and Access

EP. 8 Implementation Barriers

EP. 8 Implementation Barriers

EP. 9 Overcoming Access Challenges

EP. 9 Overcoming Access Challenges

EP. 10 Adoption Strategies

EP. 10 Adoption Strategies

EP. 11 The Metro Nashville Public Schools Initiative

EP. 11 The Metro Nashville Public Schools Initiative

EP. 12 Health Care Quality Impact

EP. 12 Health Care Quality Impact

EP. 13 Population Outcomes and Return on Value With CGMs

EP. 13 Population Outcomes and Return on Value With CGMs

EP. 14 Long-Term Outcomes Assessment

EP. 14 Long-Term Outcomes Assessment

EP. 15 Closing Perspectives

EP. 15 Closing Perspectives

Video content above is prompted by the following:

Please discuss the relative value of different CGM metrics (GMI, Ttime in Rrange, glucose variability) in assessing glycemic control.

How do these outcomes vary across different patient populations?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Managed Care Cast Director's Cut

Rewriting the AML Treatment Playbook: Tina Bhatnagar, DO

ByMaggie L. Shaw,Bhavana (Tina) Bhatnagar, DO

June 23rd 2026

Experts featured in this series.

The Right Fit First: How Psychiatrists Approach Initial Treatment and Patient Adherence

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Experts featured in this series.

Formulary Frustrations: How Insurance Constraints Shape Psychiatric Treatment Decisions

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Peopleinadoublehelix | Image Credit: © TanyaJoy-stock.adobe.com

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

ByMaggie L. Shaw

June 22nd 2026

Patientportal | Image Credit: © STBSTD-stock.adobe.com

Patient Portal Messages Outpace Office Visits

ByMaggie L. Shaw

June 22nd 2026

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention